Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sotera Health (SHC) EBITDA (2020 - 2026)

Sotera Health has reported EBITDA over the past 6 years, most recently at $50.5 million for Q4 2025.

  • For Q4 2025, EBITDA rose 170.84% year-over-year to $50.5 million; the TTM value through Dec 2025 reached $176.4 million, up 347.8%, while the annual FY2025 figure was $176.4 million, 347.8% up from the prior year.
  • EBITDA for Q4 2025 was $50.5 million at Sotera Health, up from $31.2 million in the prior quarter.
  • Over five years, EBITDA peaked at $89.1 million in Q2 2025 and troughed at -$262.4 million in Q4 2022.
  • A 5-year average of $2.0 million and a median of $6.5 million in 2021 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 3159.33% in 2022 and later surged 630.93% in 2025.
  • Year by year, EBITDA stood at $57.8 million in 2021, then tumbled by 553.54% to -$262.4 million in 2022, then surged by 122.92% to $60.1 million in 2023, then crashed by 218.57% to -$71.3 million in 2024, then surged by 170.84% to $50.5 million in 2025.
  • Business Quant data shows EBITDA for SHC at $50.5 million in Q4 2025, $31.2 million in Q3 2025, and $89.1 million in Q2 2025.